



ESHG

1967 - 2017 | 50th Anniversary Meeting

EUROPEAN SOCIETY OF HUMAN GENETICS

EUROPEAN HUMAN GENETICS CONFERENCE 2017

Bella Center | Copenhagen, Denmark | May 27 - 30



PROGRAMME

European Society
of Human Genetics

www.eshg.org
facebook.com/eshg.org

@eshgsociety
#eshg2017

Onur Eroglu
Bilecik
Turkey

E-Mail: onur.eroglu@bilecik.edu.tr

ESHG 2017 - INFORMATION ON ABSTRACT ACCEPTANCE ELECTRONIC POSTER

Dear colleague,

On behalf of the Scientific Programme Committee of the European Conference of Human Genetics 2017 taking place in Copenhagen, Denmark from May 27 to May 30, 2017 we are pleased to inform you that the abstract entitled

'Investigation of Cytotoxic and anti-proliferative effects of Betamethasone valerate (BMV) on MDA-MB 231 breast cancer cell line'
(Control No. 2017-A-2030-ESHG)

has been accepted for Electronic Poster Presentation.

Your presentation number in the programme planner and the app as well as on the presentation screens is: E- P12.05.

Schedule

Electronic Posters will be on display in the Poster Area and can be accessed at during exhibition opening hours from **Saturday, May 27 (09:30 hrs) to Monday, May 29 (17:45 hrs)** by all participants. Please personally upload your presentation upon your arrival in the Preview Centre from **Friday, May 26 from 14:00 hrs onwards** (during conference times).

Format

Please create a short presentation (either in PowerPoint or PDF) with a maximum of **4 slides** with the most important contents of your study. This is to be uploaded in the Preview Centre.

File format: **.pdf or .ppt/.pptx**

Presentation format: **16:9, portrait(!)**

The presentations will be displayed on several 42-inch touch screens in the Poster Area in portrait format.

The system will automatically generate buttons to navigate through the slides.

Withdrawal

If your electronic poster cannot be presented for any reason, please let us know as soon as possible by replying to this mail (please include the presentation or control number!).

Authors who do not notify the organising office of their cancellation ahead of the meeting and fail to present their poster, will be banned from presenting an abstract at the 2018 meeting in Milan!

With your withdrawal your abstract will be deleted from the programme planner and the conference app and it will not be published in the electronic supplement of the European Journal of Human Genetics.

The [website](#) gives more details on your presentation format (menu item "My Conference - Info for Presenters - Electronic Poster").

Please note that due to new EACCME regulations, authors are requested to disclose possible conflicts of interest on the electronic poster.

Please remember that the deadline for pre-registration fee is May 05, 2017. We also advise you to book your hotel accommodation in Copenhagen as soon as you can. Registration and hotel booking is possible on the website: www.eshg.org/eshg2017.

We look forward to welcoming you in Copenhagen in May!

With kind regards,

Joris Veltman
Chair of the Scientific Programme Committee

PS: You do not need to reply to this message in order to confirm participation.

Contact Organising Office	ESHG 2017 c/o Vienna Medical Academy Alser Str. 4 1090 Vienna, Austria	t: 0043 (0) 1 405 13 83 11 f: 0043 (0) 1 407 82 74 e: conference@eshg.org w: www.eshg.org/eshg2017
---------------------------	---	---



Welcome to the European
Human Genetics Conference
MAY 27–30, 2017

Committees

Search ...



Venue

Bella Center
Center Blvd. 5, 2300 Copenhagen S, Denmark

www.bellacentercopenhagen.dk

Conference Organisation, Abstract Management

ESHG 2017 Secretariat
c/o Vienna Medical Academy
Ms. Kristina Libova
Alser Strasse 4, A-1090 Vienna, Austria

Tel: +43 1 405 13 83 11

Fax: +43 1 407 82 74

conference@eshg.org

www.medacad.org

Exhibition, Sponsoring and Commercial Satellites

Rose International
Exhibition Management and Congress
Consultancy bv

Ms. Jantie de Roos

Ms. Flora van Laer

P.O. Box 93260, NL-2509 AG

The Hague, The Netherlands

Tel: +31 70 383 8901

Fax: +31 70 381 8936

[eshg\(at\)rose-international.com](mailto:eshg(at)rose-international.com)

www.rose-international.com

Strandvejen 169 – 171
 DK-2900 Hellerup, Denmark
 T: +46 8 5465 1500
[confirmation\(at\)mci-group.com](mailto:confirmation(at)mci-group.com)

Ms. Karin Knob
 Ms. Andrea Robinson
 Alser Strasse 4
 1090 Vienna, Austria
 T: +43 1 405 13 83 31
 F: +43 1 407 82 74
[office\(at\)eshg.org](mailto:office(at)eshg.org)
www.eshg.org

Scientific Programme Committee 2017

Chair:

Joris Veltman, Co-Chair, NL

Members:

Yanick Crow, FR
 Helene Dollfus, IT
 Francesca Forzano, Observer, IT
 Brunella Franco, IT
 Lude Franke, NL
 Cecilia Gunnarsson, SE
 Gunnar Houge, Deputy Secretary General, NO
 Erik Iwarsson, SE
 Xavier Jeunemaitre, FR
 Conxi Lazaro, ES
 Jose C. Machado, PT
 William Newman, UK
 Lucy Raymond, UK
 Alexandre Reymond, CH
 Sam Riedijk, NL
 Samuli Ripatti, FI
 Olaug K. Rødningen, NO
 Maria Jesus Sobrido, ES
 Malte Spielmann, DE
 Minna Helena Toivonen, FI

Annual Meetings Committee 2017

Chair:

Andrew Read, *Treasurer*

Members:

Gunnar Houge, *Deputy Secretary-general*
 Christine Patch, *President-elect*
 Feliciano Ramos, *Vice-President*
 Olaf Riess, *President*
 Joris Veltman, *Co-Chair of the SPC*
 Karin Witzl, *Secretary-general*

Advisors:

Jerome del Picchia
Executive Officer of the ESHG
 Kristina Libova
Conference Organiser, Vienna Medical Academy
 Jantie de Roos & Flora van Laer
Exhibition Organisers, Rose International

ESHG Executive Board 2016-2017

Gunnar Houge, *Deputy Secretary-general*
 Christine Patch, *President-elect*

Joris Veltman, Chair, NL

Thierry Voet, BE

Brunhilde Wirth, DE

Karin Witzl, Secretary General, SI

Advisor:

Jerome del Picchia, Executive Officer, AT

Karin Witzl, *Secretary-general*

Jerome del Picchia, *Executive Officer*

ESHG Conference

Secretariat

Conference@eshg.org

ESHG

ESHG Conference 2017

ESHG

ESHG

ESHG Conference

conference@eshg.org

www.eshg.org

ESHG Conference 2017



> General Terms and
Conditions

> Information
Policy

> Legal Notice

[Print this Page](#)

Presentation Abstract

Title: E-P12.05 - Investigation of Cytotoxic and anti-proliferative effects of Betamethasone valerate (BMV) on MDA-MB 231 breast cancer cell line

Keywords: Betamethasone valerate; MDA-MB-231; Breast Cancer

Authors: **O. Eroglu**^{1,2}, E. Guvenir Celik¹, H. Kaya¹, M. Celen¹;
¹Bilecik Şeyh Edebali University, Faculty of Science and Letters, Department of Molecular Biology and Genetics, Bilecik, Turkey, ²Bilecik Seyh Edebali University, Biotechnology Research Center, Bilecik, Turkey.

Abstract: Glucocorticoids play as an essential role in embryonic development, tissue homeostasis, possess anti-inflammatory and immunosuppressive. In breast cancer, glucocorticoids may have diverse effects and could inhibits chemosensitivity. Betamethasone valerate (BMV) is a synthetic glucocorticoid that is commonly used to treat psoriasis and dermatitis. The aim of this study is to explore the cytotoxicity effects and cell proliferation of using BMV in MDA-MB-231 breast cancer cell line. MDA-MB 231 breast cancer cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing Fetal Bovine Serum (FBS) 10% (v/v) and penisillin-streptomisin 1% (v/v) and incubated at 37°C in a humidified 5% CO₂ incubator. MTT assay was used to determined the cytotoxic effect range of dosage BMV (5-150 µM). Survival assay was used for determining the cytotoxic effect of drug for 24, 48 and 72 hours. After drug treatment we observed the amount of cell viability for 65 µM BMV by 61%. We treated the cells with BMV at 24, 48, 72 hours. BMV has been showed cytotoxic effects on cells after the 24 hours. In this study, we investigated how glucocorticoids play a role in breast cancer and we used BMV on MDA-MB-231 breast cancer line for the first time in literature. This results indicated that BMV treatment decreased the cell-viability on MDA-MB 231 breast cancer cell. In the future understanding the mechanism of BMV will be useful for cancer treatment.

Presentation Time: Sunday, May 28, 2017, 9:00 AM - 5:45 PM

The European Society of Human Genetics 2017